Serum markers as prognostic factors in epithelial ovanan cancer: an overview

A comprehensive review of the literature and the authors' personal experience on serum determination of tumour markers in epithelial ovarian cancer can be summarised as follows: CA 125 is the most reliable marker for monitoring the course of epithelial ovarian cancer; CA 125 assay is not an adequate screening test for this malignancy but it can represent an useful adjunct to clinical examination and ultrasound in the differential diagnosis of ovarian masses in postmenopausal women; Serial measurements of CA 125 are useful in monitoring the response to chemotherapy and follow-up. In patients with preoperative positive CA 125 assay, the concomitant determination of other tumour markers does not add further information when compared to CA 125 alone. Conversely in patients with preoperative negative assay the measurement of one or more of other antigens could be of clinical relevance.

[1] Bast R. C. Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C.: "Reactivity of a monoclonal antibody with human ovarian carcinoma". J. Clin. Invest., 1981, 68, 1331.

[2] Jacobs I., Bast R. C. Jr:'The CA 125 tumour-associated antigen: a review of the literature". Hum. Reprod., 1989, 4, 1.

[3] NHI Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up". JAMA, 1995, 273, 491.

[4] Masahashi T., Matsuzawa K., Ohsawa M., Narita O., Asai T., Ishihara M.: "Serum CA 125 levels in patients with endometriosis: Changes in CA 125 levels during menstruation". Obstet. Gynecol., 1988, 72, 328.

[5] Halila H. Stenman U. H., Seppala M.: "Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy". Cancer, I 986, 57, 1327.

[6] Kabawat S. E, Bast R. c. Jr, Wclch W. R,，knapp R C, Colvin R. B.: "Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types". Am. J. Clin. Pathol., 1983, 79, 98.

[7] Shishi J., Ghazizadeh M., Oguro T.,心hara K., Araki T.: "Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase". Am. J. Clin. Pathol., 1986, 85, 595.

[8] Einhorn N., Bast R. C. Jr, Knapp R. C., Tjernberg B., Zurawski V. R. jr: "Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer". Obstet. Gynecol., 1986, 67, 414.

[9] Zurawski V. R. Jr, Knapp R. C., Einhorn N., Kenemans P., Mortel R., Ohmi K., Bast R. C. Jr et al.: "An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma". Gynecol. Oneal., 1988, 30, 7.

[10] Gadducci A., Ferdeghini M., Prontera C., Moretti L., Mariani G., Bianchi R., Fioretti P.: "The concomitant determination of different tumor markers in patients with epitelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis". Gynecol. Oneal., 1992, 44, 147.

[11] Vasilev S. A., Schlaerth J. B., Campeau J.,M orrow C. P.: "Serum CA 125 levels in preoperative evaluation of pelvic masses". Obstet. Gynecol., 1988, 71, 751.

[12] Malkasian G. D. Jr, Knapp R. C., Lavin P. T., Zurawski V. R. Jr, Podratz K. C., Stanhope R.,M ortel R. et al.: "Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease". Am. J. Obstet. Gynecol., 1988, 159, 341.

[13] Di-Xia C., Schwartz P. E., Xinguo L., Zhan Y.: "Evaluation of CA 125 levels in differentiating malignant from benign tumors iri patients with pelvic masses". Obstet. Gynecol., 1988, 72, 23.

[14] Soper J. T.,H unter V. J.,D aly L.,T anner M.,C reasman W.T., Bast R. C. Jr: "Preoperative serum tumor-associated i antigen levels in women with pelvic masses". Obstet. Gynecol., 1990, 75, 249.

[15] Finkler N. J.,B enacerraf B.,L avin P. T.,W ojciechowski C., Knapp R. C.: "Comparison of serum CA 125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses". Obstet. Gynecol., 1988, 72, 659.

[16] Gadducci A., Capriello P., Ferdeghini M., Licata L., Puccetti A.,M adrigali A., Bianchi R.,F ioretti P.: "The combined evaluation of ultrasound, serum CA 125 assay and serum CA 19-9 assay in discriminating a benign from a malignant ovarian mass". Cancer J., 1990, 3, 252.

[17] Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., Romagnolo C. et al.: "Prospective multicenter study on CA 125 in postmenopausal pelvic masses". Gynecol. Oncol., 1994, 54, 117.

[18] SchutterE.M . J.,K enemans P.,S ohn C.,K ristenP.,C rombach G.,W estermann R.,M obus V. et al.: "Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass". Cancer, 1994, 74, 1398.

[19] Strigini F. A. L., Gadducci A., Del Bravo B., Ferdeghini M., Genazzani A. R.: "Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women". Gynecol. Oncol., 1996, 61, 68.

[20] Bast R. C. Jr, Klug T. L., Schaetzl E., Lavin P., Niloff J.M., Greber T. F., Zurawski V. R. Jr, Knapp R. C.: "Monitoring human ovarian carcinoma with a combination of CA 125, CA 19.9 and carcinoembryonic antigen". Am. J. Obstet. Gynecol., 1984, 149, 553.

[21] Canney P. A.,M oore M., Wilkinson P. M., James R. D.: "Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker". Br. J. Cancer, 1984, 50, 765.

[22] Halila H., Lehtovirta P., Stenman U. H.: "Tumor-associated trypsin inhibitor (TATI) in ovarian cancer". Br. J. Cancer, 1988, 57, 304.

[23] Fioretti P., Gadducci A., Ferdeghini M., Prontera C., Malagnino G.,F acchini V.,M ariani G.,B ianchi R.: "The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients". Gynecol. Oncol.,1992, 44, 155.

[24] Atack D. B., Nisker J. A., Allen H. H., Tustanoff E. R., Levin L.: "CA 125 surveillance and second-look laparotomy in ovarian carcinoma". Am. J. Obstet. Gynecol., 1986, 154, 287.

[25] Schilthuis M. S.,A alders J. G.,B ouma J.,K ooi H.,F leuren G. J., Willemse P.H. B., De Bruijn H. W. A. Serum CA 125 levels in epithelial ovarian cancer. Relation with findings at second-look operations and their role in the detection of tumour recurrence". Br. J. Obstet. Gynaecol., 1987, 94, 202.

[26] Podczaski E., Whitney C., Manetta A., Larson J.E., Kirk J., Stevens C. W., Lyter J.,M ortel R.: "Use of CA 125 to monitor patients with ovarian epithelial carcinomas". Gynecol. Oncol., 1989, 33, 193.

[27] Lavin P. T., Knapp R. C.,M alkasian G., Whitney C. W., Berek J. C., Bast R. C. Jr: "CA 125 for the monitoring of ovarian carcinoma during primary therapy". Obstet. Gynecol., 1987, 69, 223.

[28] Mogensen 0.,M ogensen B.,J akobsen A.: "Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer". Gynecol. Oneal., 1990, 37, 44.

[29] Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J.,M cCready V. R.: "The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma". Br. J. Obstet. Gynaecol., 1989, 96, 1395.

[30] Gadducci A., Zola P., Landoni F.,M aggino T., Sartori E., Bergamino T., Cristofani R.: "Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: "Results of a multicentric Italian study". Gynecol. Oneal., 1995, 58, 42.

[31] Niloff J. M., Knapp R. C., Lavin P. T.,M alkasian G. D., Berek J. S.,M ortel R., Whitney C. et al.: "The CA 125 assay has a predictor of clinical recurrence in epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1986, 155, 56.

[32] Zanaboni F., Presti M., Scarfone G., Bolis G.: "CA 125 reliability in predicting ovarian cancer recurrence". Tumori, 1989, 75, 69.

[33] van der Burg M. E. L., Lammes F. B., Verweij J.: "The role of CA 125 in early detection of progressive disease in ovarian cancer". Ann. Oneal., 1990, 1, 301.

[34] Hogberg T., Kagedal B.: "Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125". Gynecol. Oneal., 1992, 46, 191.

[35] Rustin G. J. S.,v an der BurgM . E. L.,B erek J. S.: "Tumour markers". Ann. Oneal., 1993, 4 (Suppl. 4), 71.

[36] Forstner R.,H ricak H., Powell C. B., Azizi L.,F rankel S. B., Stem J. L.: "Ovarian cancer recurrence: Value of M. R. Imaging". Radiology, 1995, 196, 715.

[37] Gadducci A., Sartori E., Zola P., Landoni F.,M aggino T., Palai N. Fanucchi A., Katsaros D.: "Serum CA 125 assay in the early diagnosis of recurrent epithelial ovarian cancer: a CTF study". Oneal. Rep., 1996, 3, 301.

[38] Cruickshank D. J.,F ullerton W. T., Klopper A.: "The clinical significance of pre-operative serum CA 125 in ovarian cancer". Br. J. Obstet. Gynaecol., 1987, 94, 692.

[39] Sevelda P., Schemper M., Spona J.: "CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1989, 161, 1213.

[40] Maak r A. P.,K ristensen G. B.,K aem J.,Bormer O. P.,A beler V. M., Trope C. G.: "Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis". Obstet. Gynecol., 1992, 79, 1002.

[41] Mobus V., Kreienburg R., Crombach G.: "Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer". J. Tumor Marker Oncol., 1988, 3, 251.

[42] Rosen A., Sevelda P., Klein M., Spona J., Beck A.: "A CA 125 score as a prognostic index in patients with ovarian cancer". Arch. Gynecol. Oncol., 1990, 247, 125.

[43] Cruickshank D. J.: "CA 125 parameters in survivors and nonsurvi vors with epithelial ovarian cancer". Int. J.

Gynecol. Cancer, 1991, 1, 279.

[44] Brand E., Lidor Y.: "The decline of CA 125 level after

surgery reflects the size of residual ovarian cancer". Obstet.

Gynecol., 1993, 81, 29.

[45] Yedema C., Kenemans P., T homas C., Massunger L., Wobbes T. H.,V erstraeten A.,V an Kamp G.,H ilgers J.: “CA l25 serum levels in the early post-operative period do not reflect tumor reduction obtained by cytoreductive surgery". Eur. J. Cancer, 1993, 29, 966.

[46] Gadducci A., Landoni F., Maggino T., Sartori E., Zola P., Fanucchi A.: "The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: A CTF study". Gynecol. Oncol., 1996, 63, 234.

[47] Redman C. W. E.,J ones S. R.,L uesly D. M.,N icholl S. E., Kelly K., Buxton E. J., Chan K. K., Blackledge G. R. P.: "Peritoneal trauma releases CA 125?". Br. J. Cancer, 1988, 58,502.

[48] Talbot R. W., Jacobsen D. J., Nagomey D. M., Malkasian G. D., Ritts R. E.: "Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer". S urg. Gynecol. Obstet., 1989, 168, 407.

[49] Van der Zee A. G. J., Duk J. M., Aalders J. G., Boontje A. H., Ten Hoor K. A., De Bruijn H. W. A.: "The effect of abdominal surgery on the serum concentration of the tumorassociated antigen CA 125". Br. J. Obstet. Gynaecol., 1990, 97, 934.

[50] Fayers P. M., Rustin G., Wood R., Nelstrop A., Leonard R. C. F., Wilkinson P., Cruickshank D. et al.: "On behalf of the MRC Working Party on Gynaecological Cancer. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer". Int. J. Gynecol. Cancer, 1993, 3, 285.

[51] van der Burg M. E. L., Lammes F. B., van Putten W. L. J., Stoter G.: "Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy". Gynecol. Oncol., 1988, 30, 307.

[52] Hunter V. J., Daly L., Helms M., Soper G. T., Berchuck A., Clarke-Pearson D. L., Bast R. C. Jr: "The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction". Am. J. Obstet. Gynecol., 1990, 163, 1164.

[53] Hogberg T., Kagedal B.: "Serum half-life of the. tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma". Acta Obstet. Gynecol. Scand., 1990, 69, 423.

[54] Makar A. P., Kristensen G. B., Bormer 0. P., Trope C. G.: "Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?" Gynecol. Oncol., 1993, 49, 3.

[55] Gadducci A., Landoni F., Maggino T., Sartori E., Zola P., F erdeghini M., Parma G., Cristofani R.: "Serum CA 125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study". Int. J. Gynaecol. Cancer, 1997, 7, 78.

[56] Yabushita H., Masuda T., Ogawa A., Noguchi M., Ishihara M.: "Combination assay of CA 125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer". Gynaecol. Oncol., 1988, 29, 66.

[57] Fioretti P., Gadducci A., F ederghini M., Bianchi R.: "Tumor marker association in ovarian and cervical cancer". In: "Up dating on tumor markers in tissues and in biological fluids. Basic aspects and clinical applications". (Ballesta A. M., Torre G. C., Bombardieri E., Gion M., Molina R. eds), Edizioni Minerva Medica, Torino, 1993, 737.

[58] Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., F uhrer J. P.: "Colorectal carcinoma antigens detected by hybridoma antibodies". Somatic Cell Genet., 1979, 5, 957.

[59] Charpin C., Bhan A. K., Zurawski V. R. Jr, Scully R. E.: "Carcynoembryonic antigen (CEA) and carbohydrate determinant 19.9 (CA 19.9): Localization in 121 primary and metastatic ovarian tumors. An immunohistochemical study with use of monoclonal antibodies". Int. J. Gynecol. Pathol., 1982, 1, 231.

[60] Kufe D., Inghirami G., Abe M., Hayes P., Justi-Wheeler H., Schlom J.: "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor". Hybridoma, 1984, 3, 223.

[61] Hilkens J., Kroezen V., Bonfrer J. M. G., De Jong-Bakker M., Bruning P. F.: "MAM-6 antigen, a new serum marker for breast cancer monitoring". Cancer Res., 1986, 46, 2582.

[62] Paterson A. J., Schlom J., Sears H. F., Bennett J., Cokcher D.: "A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72-3. Int. J. Cancer, 1986, 37, 659.

[63] Thor A., Gorstein F., Ohuchi N., Szpak C. A., Johnston W. W., Schlom J.: "Tumor associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72- 3". J. Natl. Cancer Inst., 1986, 76, 995.

[64] Canney P. A., Wilkinson P. M., James R. D., Moore M.: "CA 19.9 as a marker for ovarian cancer: alone and in comparison with CA 125". Br. J. Cancer, 1982, 52, 131.

[65] Scambia G., Benedetti-Panici P., Baiocchi G., Perrone L., Greggi S., Mancuso S.: "CA 15-3 as a tumor marker in gynecological malignancies". Gynaecol. Oneal., 1988, 30, 265.

[66] Gadducci A., Capriello P., F erdeghini M., Madrigali A., Puccetti A., Annichiarico C., Prontera C. et al.: "Pelvic ultrasound, serum CA 125 assay, CA 19-9 assay and serum CA 72-4 assay in the differential diagnosis of ovarian masses". Cancer J., 1991, 4, 249.

[67] Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., Romagnolo C. et al.: "Prospective multicenter study on the clinical utility of CA 72.4 in postmenopausal patients with pelvic masses". Oneal. Rep., 1995, 2, 1069.